How much revenue does Syncom Formulations (India) make?

Syncom Formulations (India) reported 4.57 billion INR in revenue for fiscal year 2025, up 76.4% from 2.59 billion INR in fiscal year 2024. In Q3 2026 revenue was 1.15 billion INR.

What is Syncom Formulations (India)'s largest business segment?

Pharmaceuticals Drugs & Formulations, with 4.70 billion INR or 97% of segment revenue in fiscal year 2025. Next: Trading of Commodities (2%) and Renting of Property (1%).

Where does Syncom Formulations (India) make most of its revenue?

Export: 84% of revenue by region in fiscal year 2025, followed by India (16%).

What companies are similar to Syncom Formulations (India)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include RPG Life Sciences Limited (RPGLIFE.NS), Gufic Biosciences Limited (GUFICBIO.NS), Unichem Laboratories Limited (UNICHEMLAB.NS), Venus Remedies Limited (VENUSREM.NS).

Syncom Formulations (India) Limited (SYNCOMF.NS) Stock

About Syncom Formulations (India) Limited

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and sus...

At a glance

Syncom Formulations (India) reported revenue of 4.57 billion INR for fiscal year 2025, up 76.4% from fiscal year 2024, and net income of 494.35 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.15 billion INR, down 9.7% from a year before. Its largest business segment, Pharmaceuticals Drugs & Formulations, brought in 97% of segment revenue in fiscal year 2025; Export was the largest region with 84%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.